获得的血友病A:对165名患者的单中心研究
Dandan Yu1,2, Feng Xue1,2, Xiaofan Liu1,2
1State Key Laboratory of Experimental Hematology, National Clinical Research Center for Blood Diseases, Haihe Laboratory of Cell Ecosystem, Tianjin Key Laboratory of Gene Therapy for Blood Diseases, CAMS Key Laboratory of Gene Therapy for Blood Diseases, Institute of Hematology and Blood Diseases Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Tianjin, China.
Research and practice in thrombosis and haemostasis
|March 4, 2024
概括
获得性血友病A (AHA) 是一种罕见的出血障碍. 免疫抑制疗法,特别是利图西马布,显示AHA的缓解率很高,特定的XVIII因子抑制剂标位和出血分数表明预后不佳.
科学领域:
- 血液学 血液学 血液学
- 免疫学 免疫学 免疫学
- 罕见疾病 罕见疾病
背景情况:
- 获得性血友病A (AHA) 是一种罕见的,异质的出血性疾病.
- 它是由第八因子 (FVIII) 抑制剂的发展引起的.
- 诊断和管理面临重大挑战,因为它的稀有性.
研究的目的:
- 为了分析AHA患者的特征.
- 为了提高对这种罕见疾病的了解.
- 为了确定AHA的有效治疗策略.
主要方法:
- 165名AHA患者的临床特征的回顾性分析.
- 1997年7月至2021年12月期间从一个单一中心收集的数据.
- 血液静止和免疫抑制疗法的评估,包括缓解率和预后因素.
主要成果:
- 诊断时的中位数年龄为45岁,诊断延迟的中位数为30天.
- 免疫抑制疗法显示出高的完全缓解 (CR) 率:利图西马布 (93.3%),类固醇加环胺 (85.0%) 和单独类固醇 (82.4%).
- 高FVIII抑制剂标位 (≥15BU/mL) 和出血得分 (≥6) 是CR的不良预后因素.
结论:
- 免疫抑制疗法在AHA中达到高响应率 (>80%CR).
- 含有利图西马布的疗法提供大约90%的CR.
- FVIII抑制剂标位≥5BU/mL和出血分数≥6是CR的不良预测指标.
相关概念视频
Disorders of Hemostasis
904
Hemostasis, the process that stops bleeding after a blood vessel injury, is crucial for maintaining the integrity of the circulatory system. However, disorders of hemostasis can disrupt this delicate balance, leading to either excessive clotting or bleeding. These disorders can be broadly classified into thromboembolic disorders and bleeding disorders.
Thromboembolic Disorders
Two factors primarily cause thromboembolic conditions.
Thromboembolic Disorders
Two factors primarily cause thromboembolic conditions.
904
Genome-wide Association Studies-GWAS
13.4K
Genome-wide association studies or GWAS are used to identify whether common SNPs are associated with certain diseases. Suppose specific SNPs are more frequently observed in individuals with a particular disease than those without the disease. In that case, those SNPs are said to be associated with the disease. Chi-square analysis is performed to check the probability of the allele likely to be associated with the disease.
GWAS does not require the identification of the target gene involved in...
GWAS does not require the identification of the target gene involved in...
13.4K
Anticoagulant Drugs: Low-Molecular-Weight Heparins
696
Hemostasis is a crucial process that prevents excessive blood loss from damaged blood vessels. It involves various mechanisms such as vasoconstriction, platelet adhesion and activation, and fibrin formation. The importance of each mechanism depends on the type of vessel injury. In contrast, thrombosis is the abnormal formation of a blood clot within the blood vessels, leading to potential complications if the clot obstructs blood flow. Thrombosis can be caused by increased coagulability of the...
696


